This HTML5 document contains 81 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n24http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00570/identifier/drugbank/
n8http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00570/identifier/national-drug-code-directory/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00570/identifier/chemspider/
n27http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00570/identifier/chebi/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00570/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00570/identifier/pharmgkb/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://www.drugs.com/cdi/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00570/identifier/pdb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00570/identifier/kegg-compound/
n5http://linked.opendata.cz/resource/drugbank/property/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00570/identifier/bindingdb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00570/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00570/identifier/pubchem-substance/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00570
rdf:type
n3:Drug
n3:description
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
n3:dosage
n26:271B4A7B-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Starling D: Two ultrastructurally distinct tubulin paracrystals induced in sea-urchin eggs by vinblastine sulphate. J Cell Sci. 1976 Jan;20(1):79-89. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/942954
n3:group
approved
n3:halfLife
Triphasic: 35 min, 53 min, and 19 hours
n3:indication
For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
n3:manufacturer
n4:271B4A79-363D-11E5-9242-09173F13E4C5 n4:271B4A77-363D-11E5-9242-09173F13E4C5 n4:271B4A78-363D-11E5-9242-09173F13E4C5 n4:271B4A75-363D-11E5-9242-09173F13E4C5 n4:271B4A76-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00570 n27:DB00570
dcterms:title
Vinblastine
adms:identifier
n13:Vinblastine n16:KAR n17:PA451877 n18:C07201 n19:55390-091-10 n21:241903 n22:46504550 n23:50012278 n25:DB00570 n28:27375 n29:12773
n3:mechanismOfAction
The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.
n3:packager
n4:271B4A70-363D-11E5-9242-09173F13E4C5 n4:271B4A73-363D-11E5-9242-09173F13E4C5 n4:271B4A74-363D-11E5-9242-09173F13E4C5 n4:271B4A71-363D-11E5-9242-09173F13E4C5 n4:271B4A72-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The major route of excretion may be through the biliary system.
n3:synonym
Vinblastina (2alpha,2'BETA,3beta,4alpha,5beta)-vincaleukoblastine VLB Vinblastine Vinblastinum Vincaleukoblastine Vinblastin
n3:toxicity
Oral, mouse: LD<sub>50</sub> = 423 mg/kg; Oral, rat: LD<sub>50</sub> = 305 mg/kg.
n7:hasAHFSCode
n8:10-00-00
n3:proteinBinding
98-99%
n3:salt
n3:synthesisReference
Pierre Potier, Pierre Mangeney, Nicole Langlois, Yves Langlois, "Process for the synthesis of vinblastine and leurosidine." U.S. Patent US4305875, issued October, 1977.
foaf:page
n11:vinblastine.html n24:vinblastine.htm
n3:IUPAC-Name
n5:271B4A80-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4A86-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4A85-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4A82-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4A83-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4A84-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4A96-363D-11E5-9242-09173F13E4C5 n5:271B4A7E-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4A98-363D-11E5-9242-09173F13E4C5 n5:271B4A7C-363D-11E5-9242-09173F13E4C5 n5:271B4A7F-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4A7D-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n9:L01CA01
n3:H-Bond-Acceptor-Count
n5:271B4A8C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4A8D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4A87-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4A88-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4A8A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4A89-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4A8B-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
865-21-4
n3:category
n3:containedIn
n6:271B4A7A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4A92-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4A94-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4A95-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4A97-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4A91-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4A90-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4A93-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4A81-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4A8E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4A8F-363D-11E5-9242-09173F13E4C5